Table 1 HNSCC Patient Characteristics
Patient characteristics | cetuximab (n = 34) % (n) | no cetuximab (n = 130) % (n) | p value |
|---|---|---|---|
Male | 71% (24) | 83% (108) | p = 0.10 |
Female | 29% (10) | 17% (22) | |
Mean age [range] | 58.8 [35–82] | 56.3 [19–80] | p = 0.22 |
Stage at diagnosis | |||
 I, II | 12% (4) | 9% (12) | p = 0.67 |
 III, IV | 88% (30) | 90% (117) | |
 Unknown | 0% (0) | 1% (1) | |
HPV status | |||
 Positive | 15% (5) | 18% (24) | p = 0.85 |
 Negative | 26% (9) | 26% (34) | |
 Unknown | 59% (20) | 52% (70) | |
Relapsed | |||
 Yes | 53% (18) | 31% (40) | p = 0.043 |
 No | 35% (12) | 58% (75) | |
 Unknown | 12% (4) | 12% (15) | |
Received radiation therapy | |||
 Yes | 74% (25) | 77% (100) | p = 0.92 |
 No | 12% (4) | 10% (13) | |
 Unknown | 15% (5) | 13% (17) | |
Treatment best response | |||
 Complete response | 26% (9) | 42% (55) | p = 0.004 |
 Partial response | 3% (1) | 2% (3) | |
 Stable disease | 3% (1) | 1% (1) | |
 Progressive disease | 21% (7) | 3% (4) | |
 Unknown | 47% (16) | 53% (69) | |